Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 205

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

The Role of Inflammation in Lung Cancer

Gomes, Mónica, Teixeira, Ana Luísa, Coelho, Ana, Araújo, António, Medeiros, Rui·2014·Advances in Experimental Medicine and Biology
DOI 10.1007/978-3-0348-0837-8_1
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/978-3-0348-0837-8_1

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 116

  1. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G (2006) Inflammation and cancer: how hot is the link? Biochem Pharmacol 72(11):1605–1621. doi:10.1016/j.bcp.2006.06.029 · DOI · Paper page
  2. Aggarwal BB, Vijayalekshmi RV, Sung B (2009) Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 15(2):425–430. doi:10.1158/1078-0432.CCR-08-0149 · DOI
  3. Araujo A, Ribeiro R, Azevedo I, Coelho A, Soares M, Sousa B, Pinto D, Lopes C, Medeiros R, Scagliotti GV (2007) Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer—A review of the literature. Oncologist 12(2):201–210. doi:10.1634/theoncologist.12-2-201 · DOI
  4. Asselin-Paturel C, Megherat S, Vergnon I, Echchakir H, Dorothee G, Blesson S, Gay F, Mami-Chouaib F, Chouaib S (2001) Differential effect of high doses versus low doses of interleukin-12 on the adoptive transfer of human specific cytotoxic T lymphocyte in autologous lung tumors engrafted into severe combined immunodeficiency disease-nonobese diabetic mice: relation with interleukin-10 induction. Cancer 91(1):113–122 · DOI
  5. Atkinson JJ, Senior RM (2003) Matrix metalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol 28(1):12–24. doi:10.1165/rcmb.2002-0166TR · DOI · Paper page
  6. Azevedo A, Cunha V, Teixeira AL, Medeiros R (2011) IL-6/IL-6R as a potential key signaling pathway in prostate cancer development. World J Clin Oncol 2(12):384–396. doi:10.5306/wjco.v2.i12.384 · DOI
  7. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357(9255):539–545. doi:10.1016/S0140-6736(00)04046-0 · DOI · Paper page
  8. Ballaz S, Mulshine JL (2003) The potential contributions of chronic inflammation to lung carcinogenesis. Clin Lung Cancer 5(1):46–62. doi:10.3816/CLC.2003.n.021 · DOI
  9. Baruch RR, Melinscak H, Lo J, Liu Y, Yeung O, Hurta RA (2001) Altered matrix metalloproteinase expression associated with oncogene-mediated cellular transformation and metastasis formation. Cell Biol Int 25(5):411–420. doi:10.1006/cbir.2000.0647 · DOI
  10. Ben-Baruch A (2006) Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 16(1):38–52. doi:10.1016/j.semcancer.2005.07.006 · DOI
  11. Bihl M, Tamm M, Nauck M, Wieland H, Perruchoud AP, Roth M (1998) Proliferation of human non-small-cell lung cancer cell lines: role of interleukin-6. Am J Respir Cell Mol Biol 19(4):606–612. doi:10.1165/ajrcmb.19.4.3247 · DOI
  12. Borczuk AC, Papanikolaou N, Toonkel RL, Sole M, Gorenstein LA, Ginsburg ME, Sonett JR, Friedman RA, Powell CA (2008) Lung adenocarcinoma invasion in TGFbetaRII-deficient cells is mediated by CCL5/RANTES. Oncogene 27(4):557–564. doi:10.1038/sj.onc.1210662 · DOI
  13. Brabender J, Park J, Metzger R, Schneider PM, Lord RV, Holscher AH, Danenberg KD, Danenberg PV (2002) Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Ann Surg 235(3):440–443 · DOI
  14. Bremnes RM, Al-Shibli K, Donnem T, Sirera R, Al-Saad S, Andersen S, Stenvold H, Camps C, Busund LT (2011) The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J Thoracic Oncol: Official Pub Int Assoc Study Lung Cancer 6(4):824–833. doi:10.1097/JTO.0b013e3182037b76 · DOI
  15. Brody JS, Spira A (2006) State of the art. Chronic obstructive pulmonary disease, inflammation, and lung cancer. Proc Am Thorc Soc 3(6):535–537. doi:10.1513/pats.200603-089MS · DOI
  16. Brown PD, Bloxidge RE, Stuart NS, Gatter KC, Carmichael J (1993) Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst 85(7):574–578 · DOI
  17. Bruno A, Focaccetti C, Pagani A, Imperatori AS, Spagnoletti M, Rotolo N, Cantelmo AR, Franzi F, Capella C, Ferlazzo G, Mortara L, Albini A, Noonan DM (2013) The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer. Neoplasia 15(2):133–142 · DOI
  18. Chang KT, Huang CY, Tsai CM, Chiu CH, Lok YY (2005) Role of IL-6 in neuroendocrine differentiation and chemosensitivity of non-small cell lung cancer. Am J Physiol Lung Cell Mol Physiol 289(3):L438–L445. doi:10.1152/ajplung.00033.2005 · DOI
  19. Chen W, Li Z, Bai L, Lin Y (2011) NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target. Front Biosci: J Virtual Libr 16:1172–1185 · DOI
  20. Coelho A, Calcada C, Catarino R, Pinto D, Fonseca G, Medeiros R (2006) CXCL12-3’ A polymorphism and lung cancer metastases protection: new perspectives in immunotherapy? Cancer Immunol Immunother 55(6):639–643. doi:10.1007/s00262-005-0062-1 · DOI
  21. Cohen S (1965) The stimulation of epidermal proliferation by a specific protein (EGF). Dev Biol 12(3):394–407 · DOI
  22. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ, Thun M (2009) Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10(5):501–507. doi:10.1016/S1470-2045(09)70035-X · DOI
  23. Dalwadi H, Krysan K, Heuze-Vourc’h N, Dohadwala M, Elashoff D, Sharma S, Cacalano N, Lichtenstein A, Dubinett S (2005) Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer. Clin Cancer Res 11(21):7674–7682. doi:10.1158/1078-0432.CCR-05-1205 · DOI
  24. de Mello RA, Marques DS, Medeiros R, Araujo AM (2011) Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies. World J Clin Oncol 2(11):367–376. doi:10.5306/wjco.v2.i11.367 · DOI
  25. de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6(1):24–37. doi:10.1038/nrc1782 · DOI
  26. De Vita F, Orditura M, Auriemma A, Infusino S, Roscigno A, Catalano G (1998) Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncol Rep 5(3):649–652
  27. De Vita F, Orditura M, Galizia G, Romano C, Roscigno A, Lieto E, Catalano G (2000) Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest 117(2):365–373 · DOI
  28. Deryugina EI, Quigley JP (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25(1):9–34. doi:10.1007/s10555-006-7886-9 · DOI
  29. Dubinett SM, Sharma S, Huang M, Dohadwala M, Pold M, Mao JT (2003) Cyclooxygenase-2 in lung cancer. Prog Exp Tumor Res 37:138–162 · DOI
  30. Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Brocker EB (1995) Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 5(1):67–68 · DOI
  31. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3(11):991–998. doi:10.1038/ni1102-991 · DOI · Paper page
  32. Duperron C, Castonguay A (1997) Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carcinogenesis 18(5):1001–1006 · DOI
  33. Elgert KD, Alleva DG, Mullins DW (1998) Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 64(3):275–290 · DOI
  34. Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46(4):765–781. doi:10.1016/j.ejca.2009.12.014 · DOI
  35. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18(12):2354–2362 · DOI
  36. Gomes M, Coelho A, Araújo A, Catarino R, Medeiros R (2011) 1137 POSTER Is MMP-9 Q279R a possible marker of prognostic in non small cell lung cancer? Eur J Cancer (Oxford 1990) 47:S134–S135 · DOI
  37. Gomes M, Coelho A, Araujo A, Teixeira AL, Catarino R, Medeiros R (2012) Influence of functional genetic polymorphism (−590C/T) in non-small cell lung cancer (NSCLC) development: the paradoxal role of IL-4. Gene 504(1):111–115. doi:10.1016/j.gene.2012.05.008 · DOI
  38. Gonzalez-Arriaga P, Pascual T, Garcia-Alvarez A, Fernandez-Somoano A, Lopez-Cima MF, Tardon A (2012) Genetic polymorphisms in MMP 2, 9 and 3 genes modify lung cancer risk and survival. BMC Cancer 12:121. doi:10.1186/1471-2407-12-121 · DOI
  39. Gregory AD, Houghton AM (2011) Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res 71(7):2411–2416. doi:10.1158/0008-5472.CAN-10-2583 · DOI
  40. Gupta RA, Dubois RN (2001) Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1(1):11–21. doi:10.1038/35094017 · DOI
  41. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. doi:10.1016/j.cell.2011.02.013 · DOI · Paper page
  42. Harris RE, Beebe-Donk J, Alshafie GA (2007) Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study. Int J Biol Sci 3(5):328–334 · DOI
  43. Hatanaka H, Abe Y, Kamiya T, Morino F, Nagata J, Tokunaga T, Oshika Y, Suemizu H, Kijima H, Tsuchida T, Yamazaki H, Inoue H, Nakamura M, Ueyama Y (2000) Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer. Ann Oncol 11(7):815–819 · DOI
  44. Haynes A, Shaik MS, Chatterjee A, Singh M (2003) Evaluation of an aerosolized selective COX-2 inhibitor as a potentiator of doxorubicin in a non-small-cell lung cancer cell line. Pharm Res 20(9):1485–1495 · DOI
  45. Hoffman PC, Mauer AM, Vokes EE (2000) Lung cancer. Lancet 355(9202):479–485. doi:10.1016/S0140-6736(00)82038-3 · DOI
  46. Hu Z, Huo X, Lu D, Qian J, Zhou J, Chen Y, Xu L, Ma H, Zhu J, Wei Q, Shen H (2005) Functional polymorphisms of matrix metalloproteinase-9 are associated with risk of occurrence and metastasis of lung cancer. Clin Cancer Res 11(15):5433–5439. doi:10.1158/1078-0432.CCR-05-0311 · DOI
  47. Ishihara K, Hirano T (2002) IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 13(4-5):357–368 · DOI · Paper page
  48. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ (2000) Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 60(1):184–190
  49. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90. doi:10.3322/caac.20107 · DOI · Paper page
  50. Jumper C, Cobos E, Lox C (2004) Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment. Respir Med 98(2):173–177 · DOI
  51. Karin M (2008) The IkappaB kinase—a bridge between inflammation and cancer. Cell Res 18(3):334–342. doi:10.1038/cr.2008.30 · DOI
  52. Khan N, Afaq F, Kweon MH, Kim K, Mukhtar H (2007a) Oral consumption of pomegranate fruit extract inhibits growth and progression of primary lung tumors in mice. Cancer Res 67(7):3475–3482. doi:10.1158/0008-5472.CAN-06-3941 · DOI
  53. Khan N, Hadi N, Afaq F, Syed DN, Kweon MH, Mukhtar H (2007b) Pomegranate fruit extract inhibits prosurvival pathways in human A549 lung carcinoma cells and tumor growth in athymic nude mice. Carcinogenesis 28(1):163–173. doi:10.1093/carcin/bgl145 · DOI
  54. Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, Feng L, Hong WK, Xu XC (2001) Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 7(4):861–867
  55. Koc M, Ediger D, Budak F, Karadag M, Oral HB, Uzaslan E, Ege E, Gozu RO (2006) Matrix metalloproteinase-9 (MMP-9) elevated in serum but not in bronchial lavage fluid in patients with lung cancer. Tumori 92(2):149–154 · DOI
  56. Komori A, Yatsunami J, Suganuma M, Okabe S, Abe S, Sakai A, Sasaki K, Fujiki H (1993) Tumor necrosis factor acts as a tumor promoter in BALB/3T3 cell transformation. Cancer Res 53(9):1982–1985
  57. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18):1693–1703. doi:10.1056/NEJMoa1006448 · DOI
  58. Lan Q, Zheng T, Rothman N, Zhang Y, Wang SS, Shen M, Berndt SI, Zahm SH, Holford TR, Leaderer B, Yeager M, Welch R, Boyle P, Zhang B, Zou K, Zhu Y, Chanock S (2006) Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 107(10):4101–4108. doi:10.1182/blood-2005-10-4160 · DOI
  59. Lee JM, Mao JT, Krysan K, Dubinett SM (2007) Significance of cyclooxygenase-2 in prognosis, targeted therapy and chemoprevention of NSCLC. Future Oncol 3(2):149–153. doi:10.2217/14796694.3.2.149 · DOI
  60. Li F, Liu Y, Chen H, Liao D, Shen Y, Xu F, Wang J (2011) EGFR and COX-2 protein expression in non-small cell lung cancer and the correlation with clinical features. J Exp Clin Cancer Res 30:27. doi:10.1186/1756-9966-30-27 · DOI
  61. Li Y, Yang T, Wei S, Wang J, Wang M, Wang Y, Zhou Q, Liu H, Chen J (2013) Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. PLoS One 8(1):e52093. doi:10.1371/journal.pone.0052093 · DOI
  62. Lin EY, Pollard JW (2004) Role of infiltrated leucocytes in tumour growth and spread. Br J Cancer 90(11):2053–2058. doi:10.1038/sj.bjc.6601705 · DOI
  63. Liu D, Guo H, Li Y, Xu X, Yang K, Bai Y (2012) Association between polymorphisms in the promoter regions of matrix metalloproteinases (MMPs) and risk of cancer metastasis: a meta-analysis. PLoS One 7(2):e31251. doi:10.1371/journal.pone.0031251 · DOI
  64. Liu D, Nakano J, Ishikawa S, Yokomise H, Ueno M, Kadota K, Urushihara M, Huang CL (2007) Overexpression of matrix metalloproteinase-7 (MMP-7) correlates with tumor proliferation, and a poor prognosis in non-small cell lung cancer. Lung Cancer 58(3):384–391. doi:10.1016/j.lungcan.2007.07.005 · DOI
  65. Lu H, Ouyang W, Huang C (2006) Inflammation, a key event in cancer development. Molecular cancer research : MCR 4(4):221–233. doi:10.1158/1541-7786.MCR-05-0261 · DOI
  66. Luo JL, Maeda S, Hsu LC, Yagita H, Karin M (2004) Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 6(3):297–305. doi:10.1016/j.ccr.2004.08.012 · DOI
  67. Luo X, Ding Q, Wang M, Li Z, Mao K, Sun B, Pan Y, Wang Z, Zang YQ, Chen Y (2010) In vivo disruption of TGF-beta signaling by Smad7 in airway epithelium alleviates allergic asthma but aggravates lung carcinogenesis in mouse. PLoS One 5(4):e10149. doi:10.1371/journal.pone.0010149 · DOI
  68. Mao JT, Cui X, Reckamp K, Liu M, Krysan K, Dalwadi H, Sharma S, Hazra S, Strieter R, Gardner B, Dubinett SM (2005) Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer. Clin Lung Cancer 7(1):30–39. doi:10.3816/CLC.2005.n.019 · DOI
  69. Mao JT, Roth MD, Fishbein MC, Aberle DR, Zhang ZF, Rao JY, Tashkin DP, Goodglick L, Holmes EC, Cameron RB, Dubinett SM, Elashoff R, Szabo E, Elashoff D (2011) Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev Res (Phila) 4(7):984–993. doi:10.1158/1940-6207.CAPR-11-0078 · DOI
  70. Martey CA, Pollock SJ, Turner CK, O’Reilly KM, Baglole CJ, Phipps RP, Sime PJ (2004) Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblasts: implications for lung inflammation and cancer. Am J Physiol Lung Cell Mol Physiol 287(5):L981–L991. doi:10.1152/ajplung.00239.2003 · DOI
  71. Menter DG, Schilsky RL, DuBois RN (2010) Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res 16(5):1384–1390. doi:10.1158/1078-0432.CCR-09-0788 · DOI
  72. Michalaki V, Syrigos K, Charles P, Waxman J (2004) Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 90(12):2312–2316. doi:10.1038/sj.bjc.6601814 · DOI
  73. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc Mayo Clin 83(5):584–594. doi:10.4065/83.5.584 · DOI
  74. Montuenga LM, Pio R (2007) Tumour-associated macrophages in nonsmall cell lung cancer: the role of interleukin-10. Eur Respir J 30(4):608–610. doi:10.1183/09031936.00091707 · DOI
  75. Moran CJ, Arenberg DA, Huang CC, Giordano TJ, Thomas DG, Misek DE, Chen G, Iannettoni MD, Orringer MB, Hanash S, Beer DG (2002) RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res 8(12):3803–3812
  76. Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y, Abe A (2001) Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 7(2):285–289
  77. Nogueira A, Assis J, Catarino R, Medeiros R (2013) DNA repair and cytotoxic drugs: the potential role of RAD51 in clinical outcome of non-small-cell lung cancer patients. Pharmacogenomics 14(6):689–700. doi:10.2217/pgs.13.48 · DOI
  78. O’Callaghan DS, O’Donnell D, O’Connell F, O’Byrne KJ (2010) The role of inflammation in the pathogenesis of non-small cell lung cancer. J Thoracic Oncol: Off Pub Int Assoc Study Lung Cancer 5(12):2024–2036 · DOI · Paper page
  79. Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y, Choi NC, Mathisen D, Wain J, Mark EJ, Munn LL, Jain RK (2002) Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296(5574):1883–1886. doi:10.1126/science.1071420 · DOI
  80. Peebles KA, Lee JM, Mao JT, Hazra S, Reckamp KL, Krysan K, Dohadwala M, Heinrich EL, Walser TC, Cui X, Baratelli FE, Garon E, Sharma S, Dubinett SM (2007) Inflammation and lung carcinogenesis: applying findings in prevention and treatment. Expert Rev Anticancer Ther 7(10):1405–1421. doi:10.1586/14737140.7.10.1405 · DOI
  81. Pereira C, Pimentel-Nunes P, Brandao C, Moreira-Dias L, Medeiros R, Dinis-Ribeiro M (2010) COX-2 polymorphisms and colorectal cancer risk: a strategy for chemoprevention. Eur J Gastroenterol Hepatol 22(5):607–613. doi:10.1097/MEG.0b013e3283352cbb · DOI
  82. Pine SR, Mechanic LE, Enewold L, Chaturvedi AK, Katki HA, Zheng YL, Bowman ED, Engels EA, Caporaso NE, Harris CC (2011) Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Nat Cancer Inst 103(14):1112–1122. doi:10.1093/jnci/djr216 · DOI
  83. Rao JS, Gondi C, Chetty C, Chittivelu S, Joseph PA, Lakka SS (2005) Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells. Mol Cancer Ther 4(9):1399–1408. doi:10.1158/1535-7163.MCT-05-0082 · DOI
  84. Ribeiro R, Araujo A, Lopes C, Medeiros R (2007) Immunoinflammatory mechanisms in lung cancer development: is leptin a mediator? J Thoracic Oncol: Off Pub Int Assoc Study Lung Cancer 2(2):105–108 · DOI
  85. Rioux N, Castonguay A (1998) Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res 58(23):5354–5360
  86. Roy R, Yang J, Moses MA (2009) Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 27(31):5287–5297. doi:10.1200/JCO.2009.23.5556 · DOI
  87. Schottenfeld D, Beebe-Dimmer J (2006) Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin 56(2):69–83 · DOI
  88. Serefoglou Z, Yapijakis C, Nkenke E, Vairaktaris E (2008) Genetic association of cytokine DNA polymorphisms with head and neck cancer. Oral Oncol 44(12):1093–1099. doi:10.1016/j.oraloncology.2008.02.012 · DOI
  89. Setia S, Sanyal SN (2012) Upregulation of intrinsic apoptotic pathway in NSAIDs mediated chemoprevention of experimental lung carcinogenesis. Pharmacol Rep: PR 64(3):615–624 · DOI
  90. Shih CM, Lee YL, Chiou HL, Hsu WF, Chen WE, Chou MC, Lin LY (2005) The involvement of genetic polymorphism of IL-10 promoter in non-small cell lung cancer. Lung Cancer 50(3):291–297. doi:10.1016/j.lungcan.2005.07.007 · DOI
  91. Sica A, Schioppa T, Mantovani A, Allavena P (2006) Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 42(6):717–727. doi:10.1016/j.ejca.2006.01.003 · DOI
  92. Siegel PM, Massague J (2003) Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3(11):807–821. doi:10.1038/nrc1208 · DOI
  93. Smith CJ, Perfetti TA, King JA (2006) Perspectives on pulmonary inflammation and lung cancer risk in cigarette smokers. Inhalation Toxicol 18(9):667–677. doi:10.1080/08958370600742821 · DOI
  94. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y (2004) Cytokines in cancer immunity and immunotherapy. Immunol Rev 202:275–293. doi:10.1111/j.0105-2896.2004.00199.x · DOI
  95. Srivani R, Nagarajan B (2003) A prognostic insight on in vivo expression of interleukin-6 in uterine cervical cancer. Int J Gynecol Cancer: Off J Int Gynecol Cancer Soc 13(3):331–339 · DOI
  96. Suzuki K, Kachala SS, Kadota K, Shen R, Mo Q, Beer DG, Rusch VW, Travis WD, Adusumilli PS (2011) Prognostic immune markers in non-small cell lung cancer. Clin Cancer Res 17(16):5247–5256. doi:10.1158/1078-0432.CCR-10-2805 · DOI
  97. Takeshi U, Sadar MD, Suzuki H, Akakura K, Sakamoto S, Shimbo M, Suyama T, Imamoto T, Komiya A, Yukio N, Ichikawa T (2005) Interleukin-4 in patients with prostate cancer. Anticancer Res 25(6C):4595–4598
  98. Tang J, Salama R, Gadgeel SM, Sarkar FH, Ahmad A (2013) Erlotinib resistance in lung cancer: current progress and future perspectives. Front Pharmacol 4:15. doi:10.3389/fphar.2013.00015 · DOI
  99. Teixeira AL, Araujo A, Coelho A, Ribeiro R, Gomes M, Pereira C, Medeiros R (2011) Influence of TGFB1+869T>C functional polymorphism in non-small cell lung cancer (NSCLC) risk. J Cancer Res Clin Oncol 137(3):435–439. doi:10.1007/s00432-010-0896-6 · DOI
  100. Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2(6):442–454. doi:10.1038/nrc822 · DOI
  101. Toi M, Bicknell R, Harris AL (1992) Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res 52(2):275–279
  102. Tsai CC, Chen CC, Lin CC, Chen CH, Lin TS, Shieh TY (1999) Interleukin-1 beta in oral submucous fibrosis, verrucous hyperplasia and squamous cell carcinoma tissues. Kaohsiung J Med Sci 15(9):513–519
  103. Umekawa K, Kimura T, Kudoh S, Suzumura T, Oka T, Nagata M, Mitsuoka S, Matsuura K, Nakai T, Yoshimura N, Kira Y, Hirata K (2013) Plasma RANTES, IL-10, and IL-8 levels in non–small-cell lung cancer patients treated with EGFR-TKIs. BMC Res Notes 6(1):139. doi:10.1186/1756-0500-6-139 · DOI
  104. Vaish V, Sanyal SN (2011) Chemopreventive effects of NSAIDs on cytokines and transcription factors during the early stages of colorectal cancer. Pharmacol Rep: PR 63(5):1210–1221 · DOI
  105. Van Ginderachter JA, Movahedi K, Hassanzadeh Ghassabeh G, Meerschaut S, Beschin A, Raes G, De Baetselier P (2006) Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion. Immunobiology 211(6–8):487–501. doi:10.1016/j.imbio.2006.06.002 · DOI
  106. Vihinen P, Kahari VM (2002) Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 99(2):157–166. doi:10.1002/ijc.10329 · DOI
  107. Wang HW, Joyce JA (2010) Alternative activation of tumor-associated macrophages by IL-4: priming for protumoral functions. Cell Cycle 9(24):4824–4835 · DOI
  108. Wang YC, Sung WW, Wu TC, Wang L, Chien WP, Cheng YW, Chen CY, Shieh SH, Lee H (2012) Interleukin-10 haplotype may predict survival and relapse in resected non-small cell lung cancer. PLoS One 7(7):e39525. doi:10.1371/journal.pone.0039525 · DOI
  109. Wu K, House L, Liu W, Cho WC (2012) Personalized targeted therapy for lung cancer. Int J Mol Sci 13(9):11471–11496. doi:10.3390/ijms130911471 · DOI
  110. Yan B, Wang H, Rabbani ZN, Zhao Y, Li W, Yuan Y, Li F, Dewhirst MW, Li CY (2006) Tumor necrosis factor-alpha is a potent endogenous mutagen that promotes cellular transformation. Cancer Res 66(24):11565–11570. doi:10.1158/0008-5472.CAN-06-2540 · DOI
  111. Yanagawa H, Sone S, Takahashi Y, Haku T, Yano S, Shinohara T, Ogura T (1995) Serum levels of interleukin 6 in patients with lung cancer. Br J Cancer 71(5):1095–1098 · DOI
  112. Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z, Bubici C, Mossman BT, Pass HI, Testa JR, Franzoso G, Carbone M (2006) TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA 103(27):10397–10402. doi:10.1073/pnas.0604008103 · DOI · Paper page
  113. Ye ZB, Ma T, Li H, Jin XL, Xu HM (2007) Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma. World J Gastroenterol 13(11):1747–1751 · DOI
  114. Zeni E, Mazzetti L, Miotto D, Lo Cascio N, Maestrelli P, Querzoli P, Pedriali M, De Rosa E, Fabbri LM, Mapp CE, Boschetto P (2007) Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer. Eur Respir J 30(4):627–632. doi:10.1183/09031936.00129306 · DOI
  115. Zhan P, Qian Q, Yu LK (2013) Prognostic value of COX-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis. J Thoracic Dis 5(1):40–47. doi:10.3978/j.issn.2072-1439.2013.01.02 · DOI
  116. Zucker S, Lysik RM, Malik M, Bauer BA, Caamano J, Klein-Szanto AJ (1992) Secretion of gelatinases and tissue inhibitors of metalloproteinases by human lung cancer cell lines and revertant cell lines: not an invariant correlation with metastasis. Int J Cancer 52(3):366–371 · DOI

Cited by

Metadata

Authors
Gomes, M., Teixeira, A. L., Coelho, A., Araújo, A., & Medeiros, R.
Venue
Advances in Experimental Medicine and Biology
Publisher
Springer Basel
Published
2014
Pages
1-23
ISSN
  • 0065-2598
  • 2214-8019
DOI
10.1007/978-3-0348-0837-8_1
Cited by
205
References
12
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.